Inspire Medical Systems (NYSE:INSP) Lowered to In-Line Rating by Evercore

Inspire Medical Systems (NYSE:INSP) was downgraded by Evercore from an “outperform” rating to an “in-line” rating in a research note issued on Tuesday, MarketBeat Ratings reports. They currently have a $40.00 target price on the stock. Evercore’s price objective indicates a potential downside of 3.73% from the company’s previous close.

A number of other equities research analysts have also recently issued reports on INSP. Stifel Nicolaus cut their price objective on shares of Inspire Medical Systems from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, May 5th. Summit Redstone set a $39.00 price target on shares of Inspire Medical Systems in a research report on Friday, May 22nd. Oppenheimer reaffirmed a “market perform” rating on shares of Inspire Medical Systems in a research note on Monday, June 15th. Piper Sandler downgraded Inspire Medical Systems from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $85.00 to $55.00 in a report on Tuesday, May 5th. Finally, Bank of America lowered Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 target price for the company. in a research note on Friday, May 22nd. Four research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $81.05.

Inspire Medical Systems Stock Performance

Inspire Medical Systems stock opened at $41.55 on Tuesday. The stock has a market cap of $1.20 billion, a P/E ratio of 9.25, a PEG ratio of 4.31 and a beta of 0.73. Inspire Medical Systems has a fifty-two week low of $38.91 and a fifty-two week high of $147.03. The firm’s fifty day moving average price is $46.49 and its 200-day moving average price is $67.80.

Inspire Medical Systems (NYSE:INSP) last announced its earnings results on Monday, May 4th. The company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.38. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. The business had revenue of $204.58 million for the quarter, compared to the consensus estimate of $200.04 million. During the same period last year, the firm posted $0.10 earnings per share. Inspire Medical Systems’s quarterly revenue was up 1.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. Sell-side analysts predict that Inspire Medical Systems will post 0.93 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in INSP. Edgestream Partners L.P. grew its holdings in shares of Inspire Medical Systems by 358.2% during the first quarter. Edgestream Partners L.P. now owns 82,268 shares of the company’s stock valued at $4,243,000 after buying an additional 64,315 shares during the last quarter. ADAR1 Capital Management LLC boosted its stake in Inspire Medical Systems by 2,601.3% during the 1st quarter. ADAR1 Capital Management LLC now owns 405,197 shares of the company’s stock valued at $20,900,000 after purchasing an additional 390,197 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Inspire Medical Systems by 1,115.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 632 shares of the company’s stock worth $33,000 after purchasing an additional 580 shares in the last quarter. California State Teachers Retirement System raised its stake in shares of Inspire Medical Systems by 31.6% in the first quarter. California State Teachers Retirement System now owns 34,473 shares of the company’s stock worth $1,778,000 after purchasing an additional 8,287 shares during the last quarter. Finally, Royal Bank of Canada lifted its holdings in shares of Inspire Medical Systems by 2,203.1% during the first quarter. Royal Bank of Canada now owns 252,971 shares of the company’s stock valued at $13,049,000 after purchasing an additional 241,987 shares in the last quarter. Institutional investors own 94.91% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.